Journal article

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II) The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial

Shankar Siva, Mathias Bressel, Tao Mai, Hien Le, Shalini Vinod, Harini de Silva, Sean Macdonald, Marketa Skala, Nicholas Hardcastle, Angela Rezo, David Pryor, Suki Gill, Braden Higgs, Kassandra Wagenfuehr, Rebecca Montgomery, Raef Awad, Brent Chesson, Thomas Eade, Wenchang Wong, Giuseppe Sasso Show all

JAMA ONCOLOGY | AMER MEDICAL ASSOC | Published : 2021

Abstract

Importance: Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases. Objective: To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients with pulmonary oligometastases. Design, Setting, and Participants: This multicenter, unblinded, phase 2 randomized clinical trial of 90 patients across 13 centers in Australia and New Zealand enrolled patients with 1 to 3 lung oligometastases less than or equal to 5 cm from any nonhematologic malignant tumors located away from the central airways, Eastern Cooperative Oncology Group performance..

View full abstract

Grants

Awarded by Priority-Driven Collaborative Cancer Research Scheme from Cancer Australia


Awarded by Auckland Medical Research Foundation


Awarded by National Health and Medical Research Council fellowship


Funding Acknowledgements

This study was funded by the Priority-Driven Collaborative Cancer Research Scheme APP1082399 from Cancer Australia and by grant APP2116004 from the Auckland Medical Research Foundation. The translational substudy was supported by Varian Medical Systems (Palo Alto, California) and the Victorian Cancer Center Immunotherapy program. Dr Siva was supported by a National Health and Medical Research Council fellowship (APP1122347) and a Cancer Council Victoria Colebatch Fellowship. This study was sponsored by the Trans Tasman Radiation Oncology Group.